A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer

• DOI: 10.32604/oncologie.2022.019881
• Publication Date: 2022-03-11T06:47:46Z
• Authors: Jiayi Huang; Xue Bai; Xiaofeng Xie; Liping Chen; Xiaofeng Lan; Qiuyi Zhang; Lin Song; Pengjiao Hong; Caiwen Du
• Keywords: Vinorelbine; Leukopenia

Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, China. The current study aimed explore efficacy and safety of vinorelbine patients clinical practice. Methods: A total 194 received treatment between February 2017 January 2021 at National Cancer Center/National Clinical Research Center Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy Medical Sciences Peking Union College. efficacy, terms progression-free survival overall survival, were evaluated. Results: At median follow-up period 17.0 months, 152 finally exhibited disease progression, 55 succumbed disease. During follow-up, 53 demonstrated partial response, 106 achieved stable disease, an objective response rate 27.3%. Additionally, 118 ≥24 weeks, benefit 60.8%. was 6.2 months (95% confidence interval, 5.0–7.4), not No treatment-associated mortalities occurred. most common adverse events included leukopenia (73.2%), neutropenia (72.7%), anemia (65.5%), diarrhea (46.9%). Conclusions: Oral appears efficacious acceptable toxicity use